Overview

Soluble Epoxide Hydrolase Inhibition and Insulin Resistance

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
AIM 1: The purpose of this study is to test how genetic factors may affect the activity of an enzyme the body produces, the sensitivity of the body to insulin, and blood flow in tissues in the body. AIM 2: The purpose of this study is to test how soluble epoxide hydrolase (sEH) inhibition with GSK2256294 affects tissue sEH activity and insulin sensitivity.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)